Alcoholism & Drug Abuse Weekly最新文献

{"title":"RCT: Semaglutide reduces alcohol craving and consumption","authors":"Alison Knopf","doi":"10.1002/adaw.34470","DOIUrl":"https://doi.org/10.1002/adaw.34470","url":null,"abstract":"<p>A randomized clinical trial found that once-weekly semaglutide reduced the amount of alcohol consumed over 9 weeks of treatment. A drug originally developed to treat diabetes and now commonly used to treat obesity, semaglutide has for years held promise as a treatment for alchool use disorder (AUD) (see <i>ADAW</i> https://onlinelibrary.wiley.com/doi/10.1002/adaw.34157). Just as semaglutide reduces the appetite for food, it can reduce craving for alcohol. The researchers also found that people with AUD who also smoked had greater reductions in smoking as well as in drinking. Participants received 0.25 mg/week for 4 weeks, 0.5 mg/week for 4 weeks, and 1.0 mg for 1 week, or placebo at weekly clinic visits.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"37 13","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three new studies highlight risks of cannabis use","authors":"Alison Knopf","doi":"10.1002/adaw.34465","DOIUrl":"https://doi.org/10.1002/adaw.34465","url":null,"abstract":"<p>Added to the many studies in the literature detailing the risks of cannabis use, particularly early onset psychosis in young people (see <i>ADAW</i> https://onlinelibrary.wiley.com/doi/10.1002/adaw.34321), three reports issued this month highlight new risks. One study focuses on the detrimental effects of human maternal use on offspring; the other two on the links between cannabis use and heart attacks.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"37 13","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nicotine concentrations increasing for youths who vape","authors":"Alison Knopf","doi":"10.1002/adaw.34469","DOIUrl":"https://doi.org/10.1002/adaw.34469","url":null,"abstract":"<p>Young people who vape nicotine are consuming a higher concentration than ever, and they don't even know it, a recent study has found. The maximum concentration in 2019, when youth vaping peaked, was 5% inf most e-cigarette products. That is already very high, but a recent decision by the Food and Drug Administration (FDA) has authorized 6% concentration, and there are no required concentration limits or labeling requirements. Young people obtain unpackaged devices without knowing the concentrations at all. So researchers investigated the prevalence of vaping nicotine by youth.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"37 13","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Organizations demonstrate strength despite current environment","authors":"Alison Knopf","doi":"10.1002/adaw.34467","DOIUrl":"https://doi.org/10.1002/adaw.34467","url":null,"abstract":"<p>Last week the National Association of Addiction Treatment Providers (NAATP) and CADCA, the predominant treatment and prevention organizations in the field, sent out words of encouragement to the field. The messages came at a time of funding cutbacks from the federal government.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"37 13","pages":"3-4"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Former FDA officials on prescription stimulant shortages","authors":"Alison Knopf","doi":"10.1002/adaw.34471","DOIUrl":"https://doi.org/10.1002/adaw.34471","url":null,"abstract":"<p>Sortages of prescription stimulants, used to treat attention deficit-hyperactivity disorder (ADHD), are mainly due to a dramatic increase in adults prescribed the medications, according to a Viewpoint published online March 26 in <i>JAMA Psychiatry</i>. There is also a problem with nonmedical use of prescription stimulants, the article stated. The warning signs come from the opioid overdose epidemic, which began with prescribed opioids, according to the article. “Given the association between increased prescribing of opioids with the overdose crisis, it is reasonable to examine whether the observed increase in stimulant prescribing is associated with increased misuse of these medications and associated harms,” the authors write, citing in particular “potential inappropriate prescribing by telemedicine companies that may increase the likelihood of subsequent nonmedical use.” However, despite increased prescribing, there is no documented increase in nonmedical use, the article stated, adding that in general “nonmedical use tends to be sporadic for the specific intended purpose of improving performance.” Still, the overall public health effects of the growing use of prescription stimulants by adults are not known, the authors write. “The Department of Health and Human Services is working to address many of these knowledge gaps,” with the Food and Drug Administration (FDA) analyzing data from emergency department encounters, poison centers, treatment center admissions, and more. However, studies that measure the journal of patients with ADHD from diagnosis to treatment, including sharing of medications with others, are needed, according to the authors. The FDA has a Drug Shortages Staff what works to understand the risk of shortages and to respond, partly by working with manufacturers to overcome production hurdles. “For example, to support production increases, the Drug Shortages Staff can help manufacturers get expedited reviews and inquire about current manufacturing capabilities and possible manufacturing site additions.” The article, “Prescription Stimulant Prescribing, Nonmedical Use, and Shortages: US FDA Research and Response” is by Joshua P. Rising, M.D., and Robert M. Califf, M.D. Until January 2025, Califf was FDA commissioner and Rising was senior clinical advisor to the FDA.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"37 13","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Case You Haven't Heard…","authors":"","doi":"10.1002/adaw.34473","DOIUrl":"https://doi.org/10.1002/adaw.34473","url":null,"abstract":"<p>“Funny how that works.” Yes. A perceptive insight from <i>ASAM Weekly</i> in last week's issue. “Surveying data can even help keep payers honest…sometimes. An analysis of Medicaid benefits documentation found that less than half of managed care plans (MCP) provide all three FDA-approved medications for alcohol use disorder (MAUD). But if you spin it differently, over 90% of the same MCPs cover at least one medication for AUD. Funny how that works.” Thanks to <i>ASAM Weekly</i> editor-in-chief Nicholas Athanasiou, MD in “Alcohol Use Disorder Medication Coverage and Utilization Management in Medicaid Managed Care Plans.” The three medications, by the way, are acamprosate, disulfiram, and naltrexone. Disulfiram (Antabuse) has fallen out of favor in recent years/decades.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"37 13","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coming Up…","authors":"","doi":"10.1002/adaw.34472","DOIUrl":"https://doi.org/10.1002/adaw.34472","url":null,"abstract":"<p>The <b>Collaborative Perspectives on Addiction Meeting</b> will be held <b>April 3-5, 2025</b> in Providence, Rhode Island. For more information, go to https://www.addictionpsychology.org/conventions/cpa/2025-collaborative-perspectives-addiction-meeting</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"37 13","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Government's obligation to care for those who use drugs","authors":"Rob Kent","doi":"10.1002/adaw.34468","DOIUrl":"https://doi.org/10.1002/adaw.34468","url":null,"abstract":"<p>Government is not like a private business! It cannot just eliminate programs and services as many are protected by the laws and, in some instances, by state constitutions!</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"37 13","pages":"5"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NAATP to focus on leadership during uncertain times","authors":"Alison Knopf","doi":"10.1002/adaw.34462","DOIUrl":"https://doi.org/10.1002/adaw.34462","url":null,"abstract":"<p>The National Association of Addiction Treatment Providers (NAATP), at its annual meeting to be held this year in Seatlle in May, is not avoiding tough issues of the day. Last week the organization announced the agenda. The meeting, titled <b><i>Healthy Leadership, Healthy Treatment</i></b>, will features topics including.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"37 12","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143698887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coming Up…","authors":"","doi":"10.1002/adaw.34463","DOIUrl":"https://doi.org/10.1002/adaw.34463","url":null,"abstract":"<p>The <b>Collaborative Perspectives on Addiction Meeting</b> will be held <b>April 3-5, 2025</b> in Providence, Rhode Island. For more information, go to https://addictionpsychology.org/conventions/cpa/2025-collaborative-perspectives-addiction-meeting</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"37 12","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143698888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}